Hansa Biopharma Dirección
Dirección controles de criterios 2/4
El CEO de Hansa Biopharma es Søren Tulstrup , nombrado en Mar 2018, tiene una permanencia de 6.67 años. compensación anual total es SEK27.51M, compuesta por 30.7% salario y 69.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.085% de las acciones de la empresa, por valor de SEK1.81M. La antigüedad media del equipo directivo y de la junta directiva es de 4.8 años y 3.5 años, respectivamente.
Información clave
Søren Tulstrup
Chief Executive Officer (CEO)
SEK 27.5m
Compensación total
| Porcentaje del salario del CEO | 30.7% |
| Permanencia del CEO | 6.7yrs |
| Participación del CEO | 0.08% |
| Permanencia media de la dirección | 4.8yrs |
| Promedio de permanencia en la Junta Directiva | 3.5yrs |
Actualizaciones recientes de la dirección
Recent updates
It's Down 30% But Hansa Biopharma AB (publ) (STO:HNSA) Could Be Riskier Than It Looks
Nov 07
Hansa Biopharma AB (publ) (STO:HNSA) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Oct 20Investors Appear Satisfied With Hansa Biopharma AB (publ)'s (STO:HNSA) Prospects As Shares Rocket 28%
Aug 24Hansa Biopharma AB (publ) (STO:HNSA) Analysts Just Slashed This Year's Revenue Estimates By 11%
Jul 23Hansa Biopharma AB (publ) (STO:HNSA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Jul 21Shareholders May Be Wary Of Increasing Hansa Biopharma AB (publ)'s (STO:HNSA) CEO Compensation Package
Jun 21Hansa Biopharma AB (publ) (STO:HNSA) Looks Just Right With A 32% Price Jump
May 21Some Analysts Just Cut Their Hansa Biopharma AB (publ) (STO:HNSA) Estimates
Apr 05Analyst Estimates: Here's What Brokers Think Of Hansa Biopharma AB (publ) (STO:HNSA) After Its Yearly Report
Feb 07Hansa Biopharma AB (publ) (STO:HNSA) Not Lagging Industry On Growth Or Pricing
Dec 28Newsflash: Hansa Biopharma AB (publ) (STO:HNSA) Analysts Have Been Trimming Their Revenue Forecasts
Oct 13Does Hansa Biopharma (STO:HNSA) Have A Healthy Balance Sheet?
Sep 22Investors Holding Back On Hansa Biopharma AB (publ) (STO:HNSA)
May 31Rock star Growth Puts Hansa Biopharma (STO:HNSA) In A Position To Use Debt
Apr 03Hansa Biopharma AB (publ) (STO:HNSA) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Feb 06Need To Know: The Consensus Just Cut Its Hansa Biopharma AB (publ) (STO:HNSA) Estimates For 2023
Feb 01Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -SEK 655m |
| Jun 30 2024 | n/a | n/a | -SEK 802m |
| Mar 31 2024 | n/a | n/a | -SEK 845m |
| Dec 31 2023 | SEK 28m | SEK 8m | -SEK 832m |
| Sep 30 2023 | n/a | n/a | -SEK 856m |
| Jun 30 2023 | n/a | n/a | -SEK 759m |
| Mar 31 2023 | n/a | n/a | -SEK 678m |
| Dec 31 2022 | SEK 26m | SEK 8m | -SEK 611m |
| Sep 30 2022 | n/a | n/a | -SEK 626m |
| Jun 30 2022 | n/a | n/a | -SEK 620m |
| Mar 31 2022 | n/a | n/a | -SEK 583m |
| Dec 31 2021 | SEK 26m | SEK 7m | -SEK 548m |
| Sep 30 2021 | n/a | n/a | -SEK 491m |
| Jun 30 2021 | n/a | n/a | -SEK 465m |
| Mar 31 2021 | n/a | n/a | -SEK 431m |
| Dec 31 2020 | SEK 21m | SEK 6m | -SEK 421m |
| Sep 30 2020 | n/a | n/a | -SEK 426m |
| Jun 30 2020 | n/a | n/a | -SEK 398m |
| Mar 31 2020 | n/a | n/a | -SEK 381m |
| Dec 31 2019 | SEK 11m | SEK 5m | -SEK 360m |
| Sep 30 2019 | n/a | n/a | -SEK 330m |
| Jun 30 2019 | n/a | n/a | -SEK 298m |
| Mar 31 2019 | n/a | n/a | -SEK 274m |
| Dec 31 2018 | SEK 8m | SEK 4m | -SEK 248m |
Compensación vs. Mercado: La compensación total de Søren($USD2.50M) está por encima de la media de empresas de tamaño similar en el mercado Swedish ($USD467.89K).
Compensación vs. Ingresos: La compensación de Søren ha aumentado mientras la empresa no es rentable.
CEO
Søren Tulstrup (59 yo)
6.7yrs
Permanencia
SEK 27,505,000
Compensación
Mr. Søren Tulstrup, M.Sc, has been President and Chief Executive Officer of Hansa Biopharma AB (publ) (formerly known as Hansa Medical AB (publ)) since March 20, 2018. Mr. Tulstrup served as the Chief Exec...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President & CEO | 6.7yrs | SEK 27.51m | 0.085% SEK 1.8m | |
| Chief Financial Officer | less than a year | sin datos | sin datos | |
| Senior VP & COO | 4.8yrs | sin datos | sin datos | |
| Chief Scientific and R&D Officer | less than a year | sin datos | sin datos | |
| Vice President of Finance & Administration | 5.5yrs | sin datos | sin datos | |
| VP & Head of Investor Relations | no data | sin datos | sin datos | |
| Senior VP & Chief Human Resources Officer | 5.8yrs | sin datos | sin datos | |
| VP & Head of Business Development | no data | sin datos | sin datos | |
| Head of Science | no data | sin datos | sin datos | |
| VP & Head of Medical Affairs | no data | sin datos | sin datos | |
| VP & Head of Research and Development | 3.6yrs | sin datos | sin datos |
4.8yrs
Permanencia media
55yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de HNSA se considera experimentado (4.8 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Director | less than a year | sin datos | sin datos | |
| Independent Director | 6.5yrs | SEK 413.00k | 0.0037% SEK 78.8k | |
| Independent Director | 5.5yrs | SEK 493.00k | 0.0015% SEK 31.4k | |
| Independent Chairman of the Board | 2.4yrs | SEK 1.14m | 0.036% SEK 771.8k | |
| Independent Director | 5.5yrs | SEK 591.00k | 0.0044% SEK 94.4k | |
| Independent Director | 3.5yrs | SEK 725.00k | sin datos | |
| Chairman of European Medical Advisory Board in Transplantation | no data | sin datos | sin datos | |
| Member - European Medical Advisory Board-Transplantation & US Medical Advisory Board-Transplantation | no data | sin datos | sin datos | |
| Member of European Medical Advisory Board in Transplantation | no data | sin datos | sin datos | |
| Chairman of US Medical Advisory Board in Transplantation | no data | sin datos | sin datos | |
| Member of US Medical Advisory Board in Transplantation | no data | sin datos | sin datos | |
| Director | less than a year | sin datos | sin datos |
3.5yrs
Permanencia media
59.5yo
Promedio de edad
Junta con experiencia: La junta directiva de HNSA se considera experimentada (3.5 años de antigüedad promedio).